Review : Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region
Hepatocellular carcinoma (HCC) is the predominant primary liver cancer in many countries and is the third most common cause of cancer-related death in the Asia-Pacific region. The incidence of HCC is higher in men and in those over 40 years old. In the Asia-Pacific region, chronic hepatitis B virus...
Gespeichert in:
Veröffentlicht in: | Gut and liver 2016-03, Vol.10 (3), p.332 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | kor |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 3 |
container_start_page | 332 |
container_title | Gut and liver |
container_volume | 10 |
creator | Ran Xu Zhu Wai Kay Seto Ching Lung Lai Man Fung Yuen |
description | Hepatocellular carcinoma (HCC) is the predominant primary liver cancer in many countries and is the third most common cause of cancer-related death in the Asia-Pacific region. The incidence of HCC is higher in men and in those over 40 years old. In the Asia-Pacific region, chronic hepatitis B virus and hepatitis C virus infections are the main etiological agents; in particular, chronic hepatitis B infection (CHB) is still the major cause in all Asia-Pacific countries except for Japan. Over the past two decades, the incidence of HCC has remained stable in countries in the region except for Singapore and Hong Kong, where the incidence for both sexes is currently decreasing. Chronic hepatitis C infection (CHC) is an important cause of HCC in Japan, representing 70% of HCCs. Over the past several decades, the prevalence of CHC has been increasing in many Asia-Pacific countries, including Australia, New Zealand, and India. Despite advancements in treatment, HCC is still an important health problem because of the associated substantial mortality. An effective surveillance program could offer early diagnosis and hence better treatment options. Antiviral treatment for both CHB and CHC is effective in reducing the incidence of HCC. (Gut Liver 2016;10:332-339) |
format | Article |
fullrecord | <record><control><sourceid>kiss</sourceid><recordid>TN_cdi_kiss_primary_3429496</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><kiss_id>3429496</kiss_id><sourcerecordid>3429496</sourcerecordid><originalsourceid>FETCH-kiss_primary_34294963</originalsourceid><addsrcrecordid>eNp9yb0OgjAQAOAOmog_T-ByL0ACBUHcDMEwOBjiTi71wNNCSYsa3t7F2ekbvpnwwixNfCn30UIsnXsEQRLKdOeJc0Vvpg8coBj4Rh0bbdoJTAMlDTgaRVq_NFrI0SruTYfAPYx3gqNj9C-ouGEFFbVs-rWYN6gdbX6uxPZUXPPSf7Jz9WC5QzvVUSyzOEui__sFx1U2mA</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Review : Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region</title><source>DOAJ Directory of Open Access Journals</source><source>KoreaMed Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Ran Xu Zhu ; Wai Kay Seto ; Ching Lung Lai ; Man Fung Yuen</creator><creatorcontrib>Ran Xu Zhu ; Wai Kay Seto ; Ching Lung Lai ; Man Fung Yuen</creatorcontrib><description>Hepatocellular carcinoma (HCC) is the predominant primary liver cancer in many countries and is the third most common cause of cancer-related death in the Asia-Pacific region. The incidence of HCC is higher in men and in those over 40 years old. In the Asia-Pacific region, chronic hepatitis B virus and hepatitis C virus infections are the main etiological agents; in particular, chronic hepatitis B infection (CHB) is still the major cause in all Asia-Pacific countries except for Japan. Over the past two decades, the incidence of HCC has remained stable in countries in the region except for Singapore and Hong Kong, where the incidence for both sexes is currently decreasing. Chronic hepatitis C infection (CHC) is an important cause of HCC in Japan, representing 70% of HCCs. Over the past several decades, the prevalence of CHC has been increasing in many Asia-Pacific countries, including Australia, New Zealand, and India. Despite advancements in treatment, HCC is still an important health problem because of the associated substantial mortality. An effective surveillance program could offer early diagnosis and hence better treatment options. Antiviral treatment for both CHB and CHC is effective in reducing the incidence of HCC. (Gut Liver 2016;10:332-339)</description><identifier>ISSN: 1976-2283</identifier><language>kor</language><publisher>대한소화기내시경학회</publisher><subject>Carcinoma ; hepatocellular ; In-cidence ; Liver neoplasms ; Mortality ; Prevalence</subject><ispartof>Gut and liver, 2016-03, Vol.10 (3), p.332</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids></links><search><creatorcontrib>Ran Xu Zhu</creatorcontrib><creatorcontrib>Wai Kay Seto</creatorcontrib><creatorcontrib>Ching Lung Lai</creatorcontrib><creatorcontrib>Man Fung Yuen</creatorcontrib><title>Review : Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region</title><title>Gut and liver</title><addtitle>Gut and Liver</addtitle><description>Hepatocellular carcinoma (HCC) is the predominant primary liver cancer in many countries and is the third most common cause of cancer-related death in the Asia-Pacific region. The incidence of HCC is higher in men and in those over 40 years old. In the Asia-Pacific region, chronic hepatitis B virus and hepatitis C virus infections are the main etiological agents; in particular, chronic hepatitis B infection (CHB) is still the major cause in all Asia-Pacific countries except for Japan. Over the past two decades, the incidence of HCC has remained stable in countries in the region except for Singapore and Hong Kong, where the incidence for both sexes is currently decreasing. Chronic hepatitis C infection (CHC) is an important cause of HCC in Japan, representing 70% of HCCs. Over the past several decades, the prevalence of CHC has been increasing in many Asia-Pacific countries, including Australia, New Zealand, and India. Despite advancements in treatment, HCC is still an important health problem because of the associated substantial mortality. An effective surveillance program could offer early diagnosis and hence better treatment options. Antiviral treatment for both CHB and CHC is effective in reducing the incidence of HCC. (Gut Liver 2016;10:332-339)</description><subject>Carcinoma</subject><subject>hepatocellular</subject><subject>In-cidence</subject><subject>Liver neoplasms</subject><subject>Mortality</subject><subject>Prevalence</subject><issn>1976-2283</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNp9yb0OgjAQAOAOmog_T-ByL0ACBUHcDMEwOBjiTi71wNNCSYsa3t7F2ekbvpnwwixNfCn30UIsnXsEQRLKdOeJc0Vvpg8coBj4Rh0bbdoJTAMlDTgaRVq_NFrI0SruTYfAPYx3gqNj9C-ouGEFFbVs-rWYN6gdbX6uxPZUXPPSf7Jz9WC5QzvVUSyzOEui__sFx1U2mA</recordid><startdate>20160331</startdate><enddate>20160331</enddate><creator>Ran Xu Zhu</creator><creator>Wai Kay Seto</creator><creator>Ching Lung Lai</creator><creator>Man Fung Yuen</creator><general>대한소화기내시경학회</general><scope>HZB</scope><scope>Q5X</scope></search><sort><creationdate>20160331</creationdate><title>Review : Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region</title><author>Ran Xu Zhu ; Wai Kay Seto ; Ching Lung Lai ; Man Fung Yuen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-kiss_primary_34294963</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>kor</language><creationdate>2016</creationdate><topic>Carcinoma</topic><topic>hepatocellular</topic><topic>In-cidence</topic><topic>Liver neoplasms</topic><topic>Mortality</topic><topic>Prevalence</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ran Xu Zhu</creatorcontrib><creatorcontrib>Wai Kay Seto</creatorcontrib><creatorcontrib>Ching Lung Lai</creatorcontrib><creatorcontrib>Man Fung Yuen</creatorcontrib><collection>Korean Studies Information Service System (KISS)</collection><collection>Korean Studies Information Service System (KISS) B-Type</collection><jtitle>Gut and liver</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ran Xu Zhu</au><au>Wai Kay Seto</au><au>Ching Lung Lai</au><au>Man Fung Yuen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Review : Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region</atitle><jtitle>Gut and liver</jtitle><addtitle>Gut and Liver</addtitle><date>2016-03-31</date><risdate>2016</risdate><volume>10</volume><issue>3</issue><spage>332</spage><pages>332-</pages><issn>1976-2283</issn><abstract>Hepatocellular carcinoma (HCC) is the predominant primary liver cancer in many countries and is the third most common cause of cancer-related death in the Asia-Pacific region. The incidence of HCC is higher in men and in those over 40 years old. In the Asia-Pacific region, chronic hepatitis B virus and hepatitis C virus infections are the main etiological agents; in particular, chronic hepatitis B infection (CHB) is still the major cause in all Asia-Pacific countries except for Japan. Over the past two decades, the incidence of HCC has remained stable in countries in the region except for Singapore and Hong Kong, where the incidence for both sexes is currently decreasing. Chronic hepatitis C infection (CHC) is an important cause of HCC in Japan, representing 70% of HCCs. Over the past several decades, the prevalence of CHC has been increasing in many Asia-Pacific countries, including Australia, New Zealand, and India. Despite advancements in treatment, HCC is still an important health problem because of the associated substantial mortality. An effective surveillance program could offer early diagnosis and hence better treatment options. Antiviral treatment for both CHB and CHC is effective in reducing the incidence of HCC. (Gut Liver 2016;10:332-339)</abstract><pub>대한소화기내시경학회</pub><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1976-2283 |
ispartof | Gut and liver, 2016-03, Vol.10 (3), p.332 |
issn | 1976-2283 |
language | kor |
recordid | cdi_kiss_primary_3429496 |
source | DOAJ Directory of Open Access Journals; KoreaMed Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central |
subjects | Carcinoma hepatocellular In-cidence Liver neoplasms Mortality Prevalence |
title | Review : Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T16%3A31%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-kiss&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Review%20:%20Epidemiology%20of%20Hepatocellular%20Carcinoma%20in%20the%20Asia-Pacific%20Region&rft.jtitle=Gut%20and%20liver&rft.au=Ran%20Xu%20Zhu&rft.date=2016-03-31&rft.volume=10&rft.issue=3&rft.spage=332&rft.pages=332-&rft.issn=1976-2283&rft_id=info:doi/&rft_dat=%3Ckiss%3E3429496%3C/kiss%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_kiss_id=3429496&rfr_iscdi=true |